萩原正幸 (Masayuki HAGIWARA) - 論文

濱崎詩英留, 萩原正幸, 川端惇也, 宮澤剛史, 高橋崇志, 小森貴大, 梅澤佑太, 金子剛, 城武卓, 小山政史

泌尿器外科 38(4) 352-352 2025年4月査読有り

Early detection of myocarditis caused by immune checkpoint inhibitor therapy with nivolumab and ipilimumab for advanced recurrent renal cell carcinoma

Maki Todo, Yodo Gatate, Shintaro Nakano, Go Kaneko, Masayuki Hagiwara, Takayuki Takahashi, Yuta Umezawa, Genji Ueda, Shiho Ishikawa, Yoshinori Makino …

Cancer Immunol Immunother 74(3) 97 2025年2月査読有り

A Case of Avelumab-Resistant Upper Urothelial Carcinoma Responding to Pembrolizumab

Kotaro Yokota, Suguru Shirotake, Yu Miyama, Takayuki Takahashi, Yuta Umezawa, Masayuki Hagiwara, Go Kaneko, Masafumi Oyama

cureus 17(1) 2025年1月査読有り

Robot-Assisted Partial Cystectomy Using the "Double Bipolar Method".

Hamasaki S., Kaneko G., Yabuno A., Miyama Y., Hiruta S., Hagiwara M., Shirotake S., Yasuda M., Oyama M.

Cureus 16(6) 61610-61610 2024年6月査読有り

進行性腎細胞癌に対するnivolumab/ipilimumab併用療法後のdeferred cytoreductive nephrectomyの意義に関する臨床的検討

峰崎敦大, 城武卓, 蛭田慎之介, 梅澤佑太, 萩原正幸, 金子剛, 金尾健人, 小山政史

泌尿器外科 37 726-726 2024年6月査読有り

Double bipolar法を用いたロボット支援膀胱部分切除を子宮全摘術と同時に施行した1例

濱崎詩英留, 金子剛, 藪野彰, 蛭田慎之介, 梅澤佑太, 萩原正幸, 城武卓, 金尾健人, 小山政史

泌尿器外科 37 754-754 2024年6月査読有り

当院におけるロボット支援膀胱全摘除術及び体腔内尿路変向術の初期治療成績

金尾健人, 梅澤佑太, 高橋崇志, 峰崎敦大, 萩原正幸, 蛭田慎之介, 金子剛, 城武卓, 小山政史

泌尿器外科 37 764-764 2024年6月査読有り

Choroidal Metastasis From Papillary Renal Cell Carcinomas: A Case Report and a Review of the Literature.

Hiruta S., Kaneko G., Miyama Y., Miyasaka Y., Umezawa Y., Hagiwara M., Shirotake S., Kanao K., Yasuda M., Oyama M.

Cureus 16(5) 60191-60191 2024年5月査読有り

ペムブロリズマブが奏効したアベルマブ抵抗性腎盂癌の1例

横田広太朗, 城武卓, 蛭田慎之介, 峰崎敦大, 梅澤佑太, 高橋崇志, 萩原正幸, 金子剛, 金尾健人, 小山政史

泌尿器外科 37(3) 269-269 2024年3月査読有り

脈絡膜転移を来した乳頭状腎細胞癌の2例

蛭田慎之介, 金子剛, 金尾健人, 美山優, 梅澤佑太, 萩原正幸, 城武卓, 安田政実, 小山政史

泌尿器外科 37(3) 266-266 2024年3月査読有り

Pembrolizumab/Avelumab抵抗性進行性尿路上皮癌に対するEnfortumab vedotinの有効性

金子剛, 梅澤佑太, 萩原正幸, 城武卓, 金尾健人, 小山政史

日本癌治療学会学術集会抄録集 043 2023年10月査読有り

Dependence on the MUC1-C Oncoprotein in Classic, Variant, and Non-neuroendocrine Small Cell Lung Cancer.

Fushimi A, Morimoto Y, Ishikawa S, Yamashita N, Bhattacharya A, Daimon T, Rajabi H, Jin C, Hagiwara M, Yasumizu Y …

Mol Cancer Res 20(9) 1379-1390 2022年9月査読有り

Addiction of Merkel cell carcinoma to MUC1-C identifies a potential new target for treatment.

Morimoto Y, Fushimi A, Yamashita N, Hagiwara M, Bhattacharya A, Cheng J, Frost TC, Ahmad R, Daimon T, Huang L …

Oncogene 41(27) 3511-3523 2022年7月査読有り

Chronic Ac Targeting MUC1-C Suppresses tivation of Cytosolic Nucleotide Receptors and STING in Triple-Negative Breast Cancer.

Yamashita N., Fushimi A., Morimoto Y., Bhattacharya A., Hagiwara M., Yamamoto M., Hata T., Shapiro GI, Long MD, Liu S. …

Cancers (Basel) 14(11) 2580-2580 2022年5月査読有り

MUC1-C Dictates JUN and BAF-Mediated Chromatin Remodeling at Enhancer Signatures in Cancer Stem Cells.

Bhattacharya A., Fushimi A., Yamashita N., Hagiwara M., Morimoto Y., Rajabi H., Long MD, Abdulla M., Ahmad R., Street K. …

Mol Cancer Res 20(4) 556-567 2022年4月査読有り

MUC1-C dictates neuroendocrine lineage specification in pancreatic ductal adenocarcinomas.

Luan Z., Morimoto Y., Fushimi A., Yamashita N., Suo W., Bhattacharya A., Hagiwara M., Jin C., Kufe D.

Carcinogenesis 43(1) 67-76 2022年2月査読有り

The Significance of PARP1 as a biomarker for Predicting the Response to PD-L1 Blockade in Patients with PBRM1-mutated Clear Cell Renal Cell Carcinoma.

Hagiwara M., Fushimi A., Matsumoto K., Oya M.

Eur Urol 81(2) 145-148 2022年2月査読有り筆頭著者

MUC1-C integrates type II interferon and chromatin remodeling pathways in immunosuppression of prostate cancer.

Hagiwara M, Fushimi A, Bhattacharya A, Yamashita N, Morimoto Y, Oya M, Withers HG, Hu Q, Liu T, Liu S, Wong KK, Long MD, Kufe D

Oncoimmunology 11(1) 2029298-2029298 2022年2月査読有り筆頭著者

MUC1-C activates the PBAF chromatin remodeling complex in integrating redox balance with progression of human prostate cancer stem cells.

Hagiwara M., Fushimi A., Yamashita N., Bhattacharya A., Rajabi H., Long MD, Yasumizu Y., Oya M., Liu S., Kufe D.

Oncogene 40(30) 4930-4940 2021年7月査読有り筆頭著者

salvage radiation therapy and androgen-deprivation therapy for biochemical recurrence after radical prostatectomy.

Matsumoto K., Niwa N., Hagiwara M., Kosaka T., Takeda T., Yasumizu Y., Tanaka N., Morita S., Mizuno R., Shinojima T. …

Int J Clin Oncol 26(4) 744-752 2021年4月査読有り

MUC1-C Activates the BAF (mSWI/SNF) Complex in Prostate Cancer Stem Cells.

Hagiwara M., Yasumizu Y., Yamashita N., Rajabi H., Fushimi A., Long MD, Li W., Bhattacharya A., Ahmad R., Oya M. …

Cancer Res 81(4) 1111-1122 2021年2月査読有り筆頭著者

MUC1-C integrates activation of the IFN-γ pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer.

Yamashita N., Long M., Fushimi A., Yamamoto M., Hata T., Hagiwara M., Bhattacharya A., Hu Q., Wong KK, Liu S. …

J Immunother Cancer 9(1) 002115-002115 2021年1月査読有り

A Novel Risk-based Approach Simulating Oncological Surveillance After Radical Nephroureterectomy in Patients with Upper Tract Urothelial Carcinoma.

Shigeta K., Kikuchi E., Abe T., Hagiwara M., Ogihara K., Anno T., Umeda K., Baba Y., Sanjo T., Shojo K. …

Eur Urol Oncol 3(6) 756-763 2020年12月査読有り

Type of patients in whom biochemical recurrence after radical prostatectomy can be observed without salvage therapy.

Matsumoto K., Niwa N., Hagiwara M., Kosaka T., Tanaka N., Takeda T., Morita S., Mizuno R., Shinojima T., Hara S. …

World J Urol 38(7) 1749-1756 2020年7月査読有り

MUC1-C drives stemness in progression of colitis to colorectal cancer.

Li W., Zhang N., Jin C., Long MD, Rajabi H., Yasumizu Y., Fushimi A., Yamashita N., Hagiwara M., Zheng R. …

JCI Insight 5(12) 137112-137112 2020年6月査読有り

MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer.

Yasumizu Y., Rajabi H., Jin C., Hata T., Pitroda S., Long MD, Hagiwara M., Li W., Hu Q., Liu S. …

Nat Commun 11(1) 338-338 2020年1月査読有り

Is transperitoneal laparoscopic radical nephrectomy suitable for patients with a history of abdominal surgery?

Yanai Y., Takeda T., Miyajima A., Matsumoto K., Hagiwara M., Mizuno R., Kikuchi E., Asanuma H., Oya M.

Asian J Endosc Surg 12(4) 429-433 2019年10月査読有り

Long-Term Oncologic Outcomes of Laparoscopic Versus Open Radical Nephroureterectomy for Patients with T3N0M0 Upper Tract Urothelial Carcinoma: A Multicenter Cohort Study with Adjustment by Propensity Score Matching.

Shigeta K., Kikuchi E., Abe T., Hagiwara M., Ogihara K., Anno T., Umeda K., Baba Y., Sanjo T., Shojo K. …

Ann Surg Oncol 26(11) 3774-3781 2019年10月査読有り

Sub-classification of patients with intermediate-risk metastatic renal cell carcinoma treated with targeted therapy.

Kaneko G., Shirotake S., Nishimoto K., Miyazaki Y., Ito K., Ito Y., Hagiwara M., Kanao K., Nakagawa K., Momma T. …

Jpn J Clin Oncol 49(8) 780-785 2019年8月査読有り

Sulfasalazine could modulate the CD44v9-xCT system and enhance cisplatin-induced cytotoxic effects in metastatic bladder cancer.

Ogihara K., Kikuchi E., Okazaki S., Hagiwara M., Takeda T., Matsumoto K., Kosaka T., Mikami S., Saya H., Oya M.

Cancer Sci 110(4) 1431-1441 2019年4月査読有り

Impact of inflammatory marker levels one month after the first-line targeted therapy initiation on progression-free survival prediction in patients with metastatic clear cell renal cell carcinoma.

Ito K., Masunaga A., Tanaka N., Mizuno R., Shirotake S., Yasumizu Y., Ito Y., Miyazaki Y., Hagiwara M., Kanao K. …

Jpn J Clin Oncol 49(1) 69-76 2019年1月査読有り

Variant isoforms of CD44 involves acquisition of chemoresistance to cisplatin and has potential as a novel indicator for identifying a cisplatin-resistant population in urothelial cancer.

Hagiwara M., Kikuchi E., Tanaka N., Kosaka T., Mikami S., Saya H., Oya M.

BMC Cancer 18(1) 113-113 2018年1月査読有り筆頭著者

The Conditional Survival with Time of Intravesical Recurrence of Upper Tract Urothelial Carcinoma.

Shigeta K., Kikuchi E., Hagiwara M., Ando T., Mizuno R., Abe T., Mikami S., Miyajima A., Nakagawa K., Oya M.

J Urol 198(6) 1278-1285 2017年12月査読有り

Frequency and prognostic significance of incidental prostate cancer at radical cystectomy: Results from an international retrospective study.

Malte R., Kluth LA, Kaushik D., Boorjian SA, Abufaraj M., Foerster B., Rink M., Gust K., Roghmann F., Noldus J. …

Eur J Surg Oncol 43(11) 2193-2199 2017年11月査読有り

Obstructive azoospermia caused by low ligation of varicocele: A case report.

Hagiuda J., Ishikawa H., Hagiwara M., Kono H., Nakagawa K., Oya M.

Syst Biol Reprod Med 63(5) 338-339 2017年10月査読有り

Prolonged pneumoperitoneum time is an independent risk factor for intravesical recurrence after laparoscopic radical nephroureterectomy in upper tract urothelial carcinoma.

Shigeta K., Kikuchi E., Hagiwara M., Ando T., Mizuno R., Miyajima A., Nakagawa K., Oya M.

Surg Oncol 26(1) 73-79 2017年3月査読有り

Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with first-line and subsequent second-line targeted therapy: A proposal of the modified-IMDC risk model.

Tanaka N., Mizuno R., Yasumizu Y., Ito K., Shirotake S., Masunaga A., Ito Y., Miyazaki Y., Hagiwara M., Kanao K. …

Urol Oncol 35(2) 19-39 2017年2月査読有り

Impact of Second-Line Targeted Therapy Dose Intensity on Patients With Metastatic Renal Cell Carcinoma.

Shirotake S., Yasumizu Y., Ito K., Masunaga A., Ito Y., Miyazaki Y., Hagiwara M., Kanao K., Mikami S., Nakagawa K. …

Clin Genitourin Cancer 14(6) 575-583 2016年12月査読有り

Urinary pH Levels are Strongly Associated with Bladder Recurrence After Nephroureterectomy in Upper Tract Urothelial Carcinoma Patients with a Smoking History.

Ide H., Kikuchi E., Hagiwara M., Hayakawa N., Hongo H., Miyajima A., Oya M.

Ann Surg Oncol 23(5) 1029-1038 2016年12月査読有り

External Validation of the MSKCC and IMDC Risk Models in Patients Treated with Targeted Therapy as a First-line and Subsequent Second-line Treatment: A Japanese Multi-institutional Study.

Tanaka N., Mizuno R., Ito K., Shirotake S., Yasumizu Y., Masunaga A., Ito Y., Miyazaki Y., Hagiwara M., Kanao K. …

Eur Urol Focus 2(3) 303-309 2016年8月査読有り

Variant isoforms of CD44 expression in upper tract urothelial cancer as a predictive marker for recurrence and mortality.

Hagiwara M., Kikuchi E., Kosaka T., Mikami S., Saya H., Oya M.

Urol Oncol. 34(8) 19-26 2016年8月査読有り筆頭著者

Effect of reclassification of the IMDC model in patients with metastatic renal cell carcinoma treated with targeted therapy in the first-line and second-line settings.

Tanaka N., Mizuno R., Shirotake S., Ito K., Yasumizu Y., Masunaga A., Ito Y., Miyazaki Y., Hagiwara M., Kanao K. …

Urol Oncol 34(7) 17-25 2016年7月査読有り

Patient age was an independent predictor of cancer-specific survival in male patients with upper tract urothelial carcinoma treated by radical nephroureterectomy.

Kobayashi H., Kikuchi E., Tanaka N., Shirotake S., Miyazaki Y., Ide H., Obata J., Hoshino K., Matsumoto K., Kaneko G. …

Jpn J Clin Oncol 46(6) 554-559 2016年6月査読有り

Do metastatic upper tract urothelial carcinoma and bladder carcinoma have similar clinical responses to systemic chemotherapy? A Japanese multi-institutional experience.

Kikuchi E., Miyazaki J., Yuge K., Hagiwara M., Ichioka D., Inoue T., Kageyama S., Sugimoto M., Mitsuzuka K., Matsui Y. …

Jpn J Clin Oncol 46(2) 163-169 2016年2月査読有り

Nicotine Induces Tumor Growth and Chemoresistance through Activation of the PI3K/Akt/mTOR Pathway in Bladder Cancer.

Yuge K., Kikuchi E., Hagiwara M., Yasumizu Y., Tanaka N., Kosaka T., Miyajima A., Oya M.

Mol Cancer Ther 14(9) 2112-2120 2015年9月査読有り

Impact of Combined Use of Blood-based Inflammatory Markers on Patients with Upper Tract Urothelial Carcinoma Following Radical Nephroureterectomy: Proposal of a Cumulative Marker Score as a Novel Predictive Tool for Prognosis.

Tanaka N., Kikuchi E., Kanao K., Matsumoto K., Shirotake S., Miyazaki Y., Kobayashi H., Kaneko G., Hagiwara M., Ide H. …

Eur Urol Focus 1(1) 54-63 2015年8月査読有り

Prognostic Model for Predicting Survival in Patients with Disease Recurrence Following Radical Cystectomy.

Kluth LA, Xylinas E., Rieken M., Kent M., Ikeda M., Matsumoto K., Hagiwara M., Kikuchi E., Bing MT, Gupta A. …

Eur Urol Focus 1(1) 75-81 2015年8月査読有り

Visceral to total obesity ratio and severe hydronephrosis are independently associated with prolonged pneumoperitoneum operative time in patients undergoing laparoscopic radical nephroureterectomy for upper tract urothelial carcinoma.

Shigeta K., Kikuchi E., Hagiwara M., Hattori S., Kaneko G., Hasegawa M., Takeda T., Jinzaki M., Akita H., Miyajima A. …

Springerplus 290-290 2015年6月査読有り

Solifenacin or mirabegron could improve persistent overactive bladder symptoms after dutasteride treatment in patients with benign prostatic hyperplasia.

Maeda T., Kikuchi E., Hasegawa M., Ishioka K., Hagiwara M., Miyazaki Y., Shinojima T., Miyajima A., Oya M.

Urology 85(5) 1151-1155 2015年5月査読有り

Impact of an adjuvant chemotherapeutic regimen on the clinical outcome in high risk patients with upper tract urothelial carcinoma: a Japanese multi-institution experience.

Shirotake S., Kikuchi E., Tanaka N., Matsumoto K., Miyazaki Y., Kobayashi H., Ide H., Obata J., Hoshino K., Kaneko G. …

J Urol 193(4) 1122-1128 2015年4月査読有り